RD1103

RD1103 is a small molecule therapeutic candidate developed by the South Korean pharmaceutical company Pharmgen Science (formerly Woori Deul Pharmaceutical) for the treatment of obesity. The asset is currently positioned in the sponsor's pipeline under the "non-reimbursed" (비급여) development category. In the South Korean regulatory and commercial landscape, this classification is typically applied to drugs—such as those for weight management, hair loss, or erectile dysfunction—that are not covered by the National Health Insurance system. While the specific molecular target and mechanism of action for RD1103 have not been publicly disclosed, its classification suggests it may be a generic or an incrementally modified drug (IMD) targeting the established weight loss market.